KRAS and neoplasm: Further studies showed that SNORD50A/B could directly bind to and inhibit the activity of KRAS oncoproteins [24, 25], indicating that it may exert tumor suppressor function in tumorigenesis and tumor progression by suppressing the activity of the KRAS/RAF/MEK/ERK pathway.